OCUL
OCULAR THERAPEUTIX, INC
NASDAQ · Healthcare · Biotechnology · US
$10.89
−5.10%Price chart
Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.6x
Market Cap
$2.39B
MomentumView details →
1D Return
−5.10%
YTD Return
−10.09%
RSI (14)
56.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.6x
Market Cap
$2.39B
RSI (14)
56.2
MomentumView details →
1D Return
−5.10%
YTD Return
−10.09%
SummaryUpdated Jun 1, 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company founded in 2006 and headquartered in Bedford, Massachusetts. The company specializes in developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel-based formulation technology. Since going public in 2014, Ocular Therapeutix has evolved from a clinical-stage company into a commercial organization with marketed products and a robust pipeline of sustained-release drug delivery systems for various ocular conditions.
Similar companies
Latest newsMore news →
Ocular Therapeutix reported a second-quarter net loss of $0.35 per share, beating the Zacks Consensus Estimate of a $0.40 loss and improving from a $0.39 loss a year earlier.38d agoOcular Therapeutix granted inducement equity awards to new SVP Kelley Allison as a material inducement for her employment acceptance.80d agoOcular Therapeutix, Inc. appointed Jason S. Robins as Chief Financial Officer effective June 10, 2026.91d ago